The resurgence of infectious diseases and the emergence of infectious diseases raise questions on how to cope with the situation. The germ or clinical approach is the hegemonic biomedical paradigm. In this article, the author argues that the spread of infectious diseases has posted a challenge to the biomedical paradigm and shows how lock-in procedures maintain alternative and complementary medicine paradigms in the backyard.
American Association for the Advancement of Science. (2003). AAAS R&D funding update. Retrieved June 17, 2003, from www.aaas.org/spp/rd
2.
American College of Physicians. (2003). Facts & figures.Retrieved June 19, 2003, from www.acponline.org/ear/factsfigs.htm
3.
Angell, M. (2000). The pharmaceutical industry. To whom is it accountable?The New England Journal of Medicine, 342(25), 1902-1904.
4.
Armstrong, D., & Forelle, C. (2002, December 28). Drug officials may have broken rules on Neurontin. The Washington Post, p. B4.
5.
Astin, J. (1998). Why patients use alternative medicine: Results of a national study. The Journal of the American Medical Association, 279(19), 1548-1553.
6.
Bale, H. (2001). Head-to-head: Aids drugs. BBC News on line, 19 April, 2001. Retrieved February 12, 2005, from http://news.bbc.co.uk/1/hi/world/africa/1285677.stm
7.
Barret, A. (2001, December 7). Fifty ways to keep your patent. Business Week. Retrieved February 5, 2005, from http://www.spancoalition.org/NewNews/MainNews/12.07.01M.htm
8.
Begley, S., & Brant, M. (1994, July 3). The end of antibiotics?Newsweek, 123, 47-52.
9.
Berenson, A. (2003, May 18). Trial lawyers are now focusing on lawsuits against drug makers. The New York Times, p. 1.
10.
Block, R. (2001, March 7). AIDS activists win skirmish in South Africa. Judge Widens scope of case to detriment of drug companies. The Wall Street Journal. Retrieved February 5, 2005, from http://www.globaltreatmentaccess.org/content/press_releases/a01/030701_WSJ_sa_lawsuit.html
11.
Bodenheimer, T. (2000). Uneasy alliance—Clinical investigators and the pharmaceutical industry. The New England Journal of Medicine, 342(20), 1539-1544.
12.
Boseley, S. (2003, January 9). WHO infiltrated by food industry. The Guardian. Retrieved February 5, 2005, from http://www.guardian.co.uk/uk_news/story/0,,871228,00.html
13.
Braithwaite, J. (1984). Corporate crime in the pharmaceutical industry. New York: Routledge.
14.
Brown, P. J. (1987). Microparasites and macroparasites. Cultural Anthropology, 2(1), 155-171.
15.
Brundtland, G. H. (2001). Globalization as a force for better health. Retrieved December 3, 2002, from http://www.lse.ac.uk/collections/globalDimensions/lectures/globalisationAsAForceForBetterHealth/transcript.htm
16.
Bulletin of Science, Technology & Society. (2002). 22(5).
17.
Buse, K., & Walt, G. (2002). The World Health Organization and public-private health partnerships: In search of good global health governance. In M. Reich (Ed.), Public-private partnerships for health (pp. 169-195). Cambridge, MA: Harvard University Press.
18.
Buse, K., & Waxman, A. (2001). Public-private health partnerships: A strategy for WHO. Bulletin of the World Health Organization, 79(8), 748-754.
19.
Campaign Against Fraudulent Medical Research. (1995). The pharmaceutical drug racket. Retrieved June 19, 2003, from www.pnc.com.au/%7Ecafmr/online/research/drug.html
20.
Cant, S., & Sharma, U. (1996). Demarcation and transformation within homoeopathic knowledge. A strategy of professionalization. Social Science & Medicine, 42(4), 579-588.
21.
Center for Responsive Politics. (2003). Retrieved February 10, 2003, from www.opensecrets.org
22.
Collier, J., & Iheanacho, I. (2002). The pharmaceutical industry as an informant. Lancet, 360(9343), 1405-1409.
23.
Crawford, G.A. (2003). Complementary and alternative medicine. Reference & User Services Quarterly, 42(4), 296.
24.
Cucherat, M., Haugh, M. C., Gooch, M., & Boissel, J. P. (2000). Evidence of clinical efficacy of homeopathy. European Journal of Clinical Pharmacology, 56(27), 33.
25.
Delarue, F. (1977). L’intoxication vaccinale [Vaccination intoxication]. Paris: Editions du seuil.
26.
Department of Health. (2002). Getting ahead of the curve. Retrieved June 10, 2002, from www.doh.gov.uk
27.
Dosi, G. (1982). Technological paradigms and technological trajectories. Research Policy, 11(3), 147-162.
28.
Dublin, L. (1948). Health progress 1936-1945. New York: New York Metropolitan Life Insurance.
29.
Dukes, M. N. G. (2002). Accountability of the pharmaceutical industry. Lancet, 360(23), 1682-1684.
30.
Dürr, H. P. (2002). Are biology and medicine only physics? Building bridges between conventional and complementary medicine. Bulletin of Science, Technology & Society, 22(5), 338-351.
31.
Eisenberg, D., Davis, R. B., Ettner, S., & Appel, S. (1998). Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. The Journal of the American Medical Association, 280, 1569-1575.
32.
Environmental Media Services. (2003). Fast facts. Retrieved June 26, 2003, from www.ems.org/antibiotics/sub2_antibiotics.html
33.
Ernst, E. (1995). Effects of homoeopathy trial did not evaluate “true” homoeopathy. British Medical Journal, 311, 510-511.
34.
Evans, R., Barer, M., & Marmor, T. (Eds.). (1994). Why are some people healthy and others not? The determinants of health of populations. New York: Aldine.
35.
Evans, T. (2001). A landscape in rapid transition. Round table discussion. Bulletin of the World Health Organization, 79(8), 771-777.
36.
Farmer, P. (1996). Social inequalities and emerging infectious diseases. Emerging Infectious Diseases, 2(4), 259-269.
37.
Feder, G., & Katz, T. (2002). Randomized controlled trials for homoeopathy. British Medical Journal, 324(2), 499.
38.
Federal Trade Commission. (2001, May). Competition in the pharmaceutical marketplace: Antitrust implications of patent settlements. Report presented before the Committee on the Judiciary United States Senate, Washington, DC. Retrieved December 2, 2002, from www.ftc.gov/os/2001/05/pharmtstmy.htm
39.
Ferriman, A. (2000). WHO accused of stifling debate about infant feeding. British Medical Journal, 320, 1362.
40.
Fisher, P., & Ward, A. (1994). Medicine in Europe: Complementary medicine in Europe. British Medical Journal, 309, 107-111.
41.
Follansbee, S. (2003, March 21). Weak links in the food chain antibiotic alert. San Francisco Chronicle, p. A25.
42.
Frank, R. (2002). Integrating homeopathy and biomedicine: Medical practice and knowledge production among German homeopathic physicians. Sociology of Health & Illness, 24(6), 796-819.
43.
Galeria, J. (2001). Patents ignored. Brazil puts AIDS care before drug profits. Retrieved May 12, 2002, from www.americas.org/News/Features/200104_Brazil_AIDS_Drugs/20010401_index.asp
44.
Gallup, J., & Sachs, J. (1998). The economic burden of malaria. Cambridge, MA: Center for International Development at Harvard. Retrieved May 4, 2003, from www.cid.harvard.edu/malaria/mal_pub.htm
45.
Garanttini, S. (1997). Are me-too drugs justified?Journal of Nephrology, 10, 283-294. Retrieved September 12, 2002, from http://www.sin-italia.org/jnonline/vol10n6/garat/garat.htm
46.
Gellman, B. (2000, December 28). A turning point that left millions behind; drug discounts benefit few while protecting pharmaceutical companies’ profits series: Death watch: Aids, drugs and Africa. The Washington Post, p. A01.
47.
Grabowski, H., & Vernon, J. (1994). Return to R&D on new drug introductions in the 1980s. Journal of Health Economics, 13, 383-406.
48.
Hancock, T. (1998). Caveat partner: Reflections on partnership with the private sector. Health Promotion International, 13(3), 193-195.
49.
Hardon, A. (2001). Immunization for all? A critical look at the first GAVI partners meeting. HAI-Lights Hai Europe, 6(1). Retrieved December 30, 2002, from www.haiweb.org/pubs/hailights/mar2001/mar01_lead.html
50.
Henry, D., & Lexchin, J. (2002). The pharmaceutical industry as a medicine provider. Lancet, 360(16), 1590-1595.
51.
Hensley, S. (2003, January 24). Pharmacia nears generics deal on AIDS drug for poor nations. The Wall Street Journal. Retrieved February 5, 2005, from http://homepages.law.asu.edu/%7Edkarjala/InternationalIP/PharmaciaGenericsDealWS
52.
Hirschler, B., & Pierson, R. (2004). Lack of antibiotic research raises concerns. Retrieved March 2, 2004, from http://www.healthypages.net/newspage.asp?newsid=3999
53.
Ho, M.-W. (n.d.). Another independent scientist falls victim over finding against MMR vaccine. Retrieved June 19, 2003, from www.i-sis.org.uk/MMRautism.php
54.
Hughes, J. (1998). Addressing emerging infectious disease threats—Accomplishments and future plans [Special issue]. Emerging Infectious Diseases, 4(3).
55.
Initiative on Public-Private Partnerships for Health. (2004). Retrieved March 20, 2004, from www.ippph.org
56.
International Federation of Pharmaceutical Manufacturers Associations. (2000). TRIPS, pharmaceuticals and developing countries: Implications for health care access, drug quality band drug development. Geneva, Switzerland: Author.
57.
Jonas, W. B., Kaptchuk, T. J., & Linde, K. (2003). A critical overview of homeopathy. Annals of Internal Medicine, 138(5), 399.
58.
Jones, J. P. (2002). Ultrasonic acupuncture and the correlation between acupuncture stimulation and the activation of associated brain cortices using functional magnetic resonance imaging. Bulletin of Science, Technology & Society, 22(5), 362-370.
59.
Kettler, H. (2002). Updating the cost of a new chemical entity.Retrieved November 30, 2002, from www.ohe.org/updating.htm
60.
Kettler, H., & Towse, A. (2001). Public private partnerships (CMH Working Paper Series WG2:21). Geneva, Switzerland: Commission on Macroeconomics and Health.
61.
Kim, H. (1998). Yin and Yang: The nature of scientific explanation in a culture. Boston, MA: Twentieth World Congress of Philosophy. Retrieved March 9, 2004, from hhttp://www.bu.edu/wcp/MainScie.htm
62.
Kimball, A. M. (2000). Introduction to emerging infections. Seattle: School of Public Health and Community Medicine, University of Washington. Retrieved June 26, 2003, from http://depts.washington.edu/eminf/emerging/emerg.html
63.
Kuhn, T. S. (1962). The structure of scientific revolutions. Chicago: University of Chicago Press.
64.
Levins, R. (2000). Is capitalism a disease? The crisis in U.S. public health. Monthly Review, 52(4), 8.
65.
Linde, K., Clausius, N., Ramirez, G., Melchart, D., Eitel, F., Hedges, L. V., et al. (1997). Are the clinical effects of homoeopathy placebo effects? A meta-analysis of placebo-controlled trials. Lancet, 350, 834-843.
66.
Lob-Levyt, J. (2001). A donor perspective. Round table discussion. Bulletin of the World Health Organization, 79(8), 771-777.
67.
Lundberg, G., Paul, M., & Fritz, H. (1998). A comparison of the opinions of experts and readers as to what topics a general medical journal (JAMA) should address. The Journal of the American Medical Association, 280(3), 288-290.
68.
Mansfield, E. (1986). Patents and innovation: An empirical study. Management Science, 32(2), 173-181.
69.
Marwick, C. (1994). Advisory group insists on ‘alternative’ voice. The Journal of the American Medical Association, 272(16), 1239.
70.
McKeown, T. (1988). The origins of human disease. Oxford, UK: Oxford University Press.
71.
Montaner, J., O’Shaughnessy, M., & Schechter, M. (2001). Industry-sponsored clinical research: A double-edged sword. Lancet, 358(9296), 1893-1895.
72.
Morse, S. (1995). Factors in the emergence of infectious diseases. Emerging Infectious Diseases, 1(1), 7-15.
73.
Muraskin, W. (2002). The last years of the CVI and the birth of the GAVI. In M. Reich (Ed.), Public-private partnerships for public health (pp. 115-168). Cambridge, MA: Harvard University Press.
74.
National Council Against Health Fraud. (1994). Homeopathy: A position statement by the National Council Against Health Fraud. Skeptic, 3(1), 50-57.
75.
National Institute of Allergy and Infectious Diseases. (2000). Fact sheet. Antimicrobial resistance. Retrieved July 20, 2003, from www.niaid.nih.gov/factsheets/antimicro.htm
76.
Nelson, R., & Winter, S. (1982). An evolutionary theory of economic growth. Cambridge, MA: Harvard University Press.
77.
Ollila, E. (2003). Health-related public-private partnerships and the United Nations. In B. Deacon, E. Ollila, M. Koivusato, & P. Stubbs (Eds.), Global social governance (pp. 1-8). Helsinki, Finland: Ministry for Foreign Affairs of Finland, Department for International Development Cooperation. Retrieved April 10, 2003, from www.gaspp.org/publications/
78.
Orbinski, J. (2001). Market enticements are not enough. Round table discussion. Bulletin of the World Health Organization, 79(8), 771-777.
79.
Patlak, M. (1996). Book reopened on infectious diseases. Food and Drug Administration Consumer Magazine. Retrieved June 7, 2003, from www.fda.gov/fdac/features/396_infe.html
80.
Pollock, A., Shaoul, J., & Vickers, N. (2002). Private finance and “value for money” in NHS hospitals: A policy in search of a rationale?British Medical Journal, 324, 1205-1209.
81.
Press, E., & Washburn, J. (2000, March 1). The kept university. Atlantic Monthly. Retrieved March 3, 2003, from www.theatlantic.com
82.
Richter, J. (2003). ‘We the peoples’ or ‘we the corporations’? Critical reflections on UN-business ‘partnerships.’ Retrieved February 23, 2003, from www.ibfan.org and www.gifa.org
83.
Roy, R. (2002). Science and whole person medicine: Enormous potential in a new relationship. Bulletin of Science, Technology & Society, 22(5), 374-390.
84.
Sachs, J. (2003). Achieving the millennium development goals: Health in the developing world. Speech given at the Second Global Consultation of the Commission on Macroeconomics and Health, Geneva, Switzerland.
85.
Sampat, B. (2002). Private parts: Patents and academic research in the twentieth century. Paper presented at a symposium with the next generation leaders of science and technology policy. Retrieved June 26, 2003, from www.cspo.org
86.
Shah, S. (2003). Globalization of clinical research by the pharmaceutical industry. International Journal of Health Services, 33(1), 29-36.
87.
Shretta, R., Brugha, R., Robb, A., & Snow, R. W. (2000). Sustainability, affordability and equity of corporate drug donations: The case of Malarone. Lancet, 355, 1718-1720.
88.
Skolnick, A. A. (1994). FDA petitioned to ‘stop homeopathy scam.’The Journal of the American Medical Association, 272(15), 1154.
89.
Terris, M. (2001). The changing relationships of epidemiology and society. Journal of Public Health Policy, 22(4), 441-463.
90.
Tesh, S. N. (1988). Hidden arguments. Political ideology and disease prevention policy. New Brunswick, NJ: Rutgers University Press.
91.
Trouiller, P., Torreele, E., Olliaro, P., White, N., Foster, S., Wirth, D., et al. (2001). Drugs for neglected diseases: A failure of the market and a public health failure?Tropical Medicine & International Health, 6(11), 945-951.
92.
Vakhovskiy, A. (2001). Winning the war on AIDS, Brazil style. Hanover, NH: Dartmouth Free Press. Retrieved December 18, 2002, from www.uwire.com/content/topops081001001.html
93.
Viksveen, P. (2003). Antibiotics and the development of resistant microorganisms. Can homeotrajectory be an alternative?Homeotrajectory, 92, 99-107.
94.
Walt, G. (2000). Public private partnerships. Addressing public health needs or corporate agendas? (Report on the HAI Europe/BUKO Pharma-Kampagne Seminar). Amsterdam: Health Action International Europe.
95.
Watal, J. (2000). Intellectual property rights in the WTO: The way forward for developing countries. London: Oxford University Press.
96.
Whyfiles. (2003). Retrieved June 26, 2003, from http://whyfiles.org/038badbugs/scope.html
97.
Wise, R., Hart, T., Cars, O., & Streulens, M. (1998). Antimicrobial resistance is a major threat to public health. British Medical Journal, 317, 609-610.
98.
Woodman, R. (1999). Open letter disputes WHO hypertension guidelines. British Medical Journal, 318, 893.
99.
World Health Organization. (1999). Removing obstacles to healthy development. Retrieved June 10, 2003, from http://www.who.int/infectious-disease-report/index-rpt99.html
100.
World Health Organization. (2002). Economics of malaria control in China: Cost, performance and effectiveness of Henan’s consolidation programme. Retrieved February 5, 2005, from www.who.int/tdr/publications/publications/sebrep1.htm
101.
Yamey, G. (2001). Global campaign to eradicate malaria. British Medical Journal, 322, 1191-1192.
102.
Yamey, G. (2002). WHO in 2002. Faltering steps towards partnerships. British Medical Journal, 325, 1236-1240.
